ALK gene rearrangements have been described in 3–5% of lung adenocarcinomas (ADC), and the presence of dysregulated ALK has been described in at least 18 cancer types (reviewed in 1). Since lung cancer is a common type of cancer, an estimated 70,000 cases of non-small cell lung cancer (NSCLC) which have ALK genomic alterations occur… Read article →
Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3–5% of lung adenocarcinomas (ADC) (2–4, Figure 1), and over 20 ALK fusion partners have been implicated in non-small-cell lung cancer (NSCLC) (5). Thanks to the relatively recent development of small molecule targeted therapies, the ALK oncogene is now targetable using ALK tyrosine kinase inhibitors (TKIs)… Read article →
We’re excited to join @tbcontrollers at the 2018 National TB Conference in Palm Springs, CA to discuss changes in… https://t.co/zGstE5FNa0, Thank you @AMPath and all visitors for a great and insightful event in Rotterdam. We are looking forward to see you… https://t.co/GbVNualoEQ, QIAGEN reports results for first quarter 2018
https://t.co/WzAhoClXyy https://t.co/5FY4StmXeb, QIAGEN CEO Peer Schatz talked with us at #AMPeurope2018 about the importance of the conference, engaging with inter… https://t.co/5Ve12ahISy, Learn more about the first complete Sample to Insight #NGS solution designed for any research lab to deliver action… https://t.co/pPTXSQymv7, 